Phase 1 Study of INBRX-105, a TNFRSF9 (4-1BB) and PD-L1 Bispecific Antibody, in Patients with Select Solid Tumors

Puntos clave

• Low response rates observed with INBRX-105 treatment, raising concerns about its efficacy.
• Hepatic safety signals indicate potential for adverse events in patients treated with INBRX-105.
• Analysis focused on the effects of a bispecific antibody targeting TNFRSF9 and PD-L1.
• These findings suggest further clinical development may not be justified given the observed limitations.